Cargando…

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer

Detalles Bibliográficos
Autores principales:	Tinzl, Martina, Chen, Binshen, Chen, Shao-Yong, Semenas, Julius, Abrahamsson, Per-Anders, Dizeyi, Nishtman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298646/ https://www.ncbi.nlm.nih.gov/pubmed/30562402 http://dx.doi.org/10.1371/journal.pone.0209544

Ejemplares similares

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis
por: Wegiel, Barbara, et al.
Publicado: (2008)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions
por: Gobbo, Marina G., et al.
Publicado: (2015)

The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer
por: Larsson, Per, et al.
Publicado: (2019)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2015)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
por: Shan, Xiaochuan, et al.
Publicado: (2018)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
Publicado: (2014)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
por: Shim, Myungsun, et al.
Publicado: (2019)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
Publicado: (2014)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves
por: Marano, Francesca, et al.
Publicado: (2016)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

A 23‐Gene Classifier urine test for prostate cancer prognosis
por: Guo, Jinan, et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
por: Guo, Jinan, et al.
Publicado: (2021)

Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
por: Johnson, Heather, et al.
Publicado: (2020)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1
por: Zhang, Yiming, et al.
Publicado: (2021)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy
por: Wikström, Pernilla, et al.
Publicado: (2022)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells
por: Eskra, Jillian N., et al.
Publicado: (2019)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Androgen deprivation therapy and side effects: are GnRH antagonists safer?
por: Freedland, Stephen J, et al.
Publicado: (2020)

Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells
por: Adediran, Samusi, et al.
Publicado: (2022)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jj4vjlund6l08rgfevf7sg8i4k